Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q7L014
UPID:
DDX46_HUMAN
Alternative names:
DEAD box protein 46; PRP5 homolog
Alternative UPACC:
Q7L014; O94894; Q96EI0; Q9Y658
Background:
The Probable ATP-dependent RNA helicase DDX46, also known as DEAD box protein 46 and PRP5 homolog, is pivotal in RNA splicing processes. Its role, either prior to or during the formation of the splicing A complex, underscores its importance in the post-transcriptional regulation of gene expression.
Therapeutic significance:
Understanding the role of Probable ATP-dependent RNA helicase DDX46 could open doors to potential therapeutic strategies.